Choose Your Country or Region

Liver Cancer

Modeling Agent

N-Nitrosodiethylamine

2-Acetamidofluorene

Aristolochic acid A

Antiviral Infection ^[1]

HBV: OSS_128167; Emtricitabine; Azvudine; Bicyclol; Morphothiadin; JNJ-632; 2',3'-Dideoxyadenosine; Bay 41-4109 racemate

HCV: AG-1478; Mizoribine; Sofosbuvir; Telaprevir; Danoprevir; Boceprevir; Daclatasvir; Lomibuvir

NCCN Guidelines Recommendations ^[2]

First-Line Systemic Therapy: Atezolizumab; Bevacizumab; Sorafenib; E7080; Durvalumab; Pembrolizumab

Subsequent-Line Systemic Therapy: Regorafenib; Cabozantinib; Ramucirumab; E7080; Nivolumab; Sorafenib; Ipilimumab; Pembrolizumab; Dostarlimab

FOLFOX4 Regiment: 5-Fluorouracil; Folinic acid; Oxaliplatin

Inhibitors: Linifanib; Tivantinib; Axitinib; Apatinib

Chemotherapy

Platinum-based: Cisplatin; Carboplatin; Nedaplatin; Oxaliplatin

Alkaloids: Paclitaxel; Nab-Paclitaxel; Docetaxel

Antimetabolites: Pemetrexed; Gemcitabine; 5-Fluorouracil; Folinic acid

TOPO Inhibitors: Irinotecan; Etoposide; Topotecan; Doxorubicin; Epirubicin HCl

Alkylating Agents: Mitomycin C; Cyclophosphamide; Ifosfamide; TMZ

Immune Checkpoint Inhibitors

PD-1: Pembrolizumab; Dostarlimab; Cemiplimab; Camrelizumab; Sintilimab; Nivolumab; Serplulimab

PD-L1: Atezolizumab; Durvalumab; Avelumab; Adebrelimab; Sugemalimab

CTLA-4: Nurulimab; Zalifrelimab; Quavonlimab; Ipilimumab; Tremelimumab

Anti-Angiogenesis

FGFR: Sorafenib; Ponatinib; BGJ398; BIBF 1120; AZD4547

FLT3: Pexidartinib; Crenolanib; Foretinib; UNC2025 HCl; Fedratinib

Src: Src Inhibitor 1; WH-4-023; Saracatinib; SKI-606; Dasatinib

Syk: R406; R406; PRT062607 (P505-15) HCl; Entospletinib; Piceatannol

Mutated Genes-Targeted ^[3] ^[4]

Beta-catenin: PRI-724; RCM-1; LF3; Tegatrabetan; MSAB

p53: Nutlin-3a; Pifithrin-α (PFTα) Hhydrobromide; SAR405838; Eprenetapopt; Pifithrin-μ

MUC16: Sofituzumab vedotin; Oregovomab; Abagovomab; Sofituzumab

FGFR2: NSC12; SKLB 610; Alofanib; Pemigatinib; ASP5878

PBRM1: ACBI1

Anti-Angiogenesis (B)

VDA: Verteporfin; Vadimezan; Plinabulin

TIE2: Regorafenib; Tie2 kinase inhibitor 1; Pexmetinib; MGCD-265 analog

Angiotensin: Angiotensin II human Acetate; Angiotensin; Azilsartan; Olmesartan

TKIs

EGFR: AZD9291; Afatinib; Gefitinib; Lapatinib; Erlotinib

VEGFR: E7080; Regorafenib; Cabozantinib malate; Axitinib; Lenvatinib Mesylate

c-Met: Cabozantinib; PF-02341066; Capmatinib; Foretinib; SGX-523

PDGFR: Sorafenib; Ponatinib; Sunitinib; Imatinib; Linifanib

c-Kit: Dasatinib; Imatinib; Sorafenib tosylate; Sunitinib; Regorafenib

PI3K/Akt/mTOR

Akt: MK-2206 Dihydrochloride; Perifosine; AZD5363; SC79; GSK690693

PI3K: LY294002; 3-Methyladenine; Dactolisib; Pictilisib; Wortmannin

mTOR: Rapamycin; RAD001; Dactolisib; AZD8055; NU7441

AMPK: Nilotinib; GSK690693; Doxorubicin (Adriamycin) Hydrochloride; AICAR; Phenformin HCl

DNA-PK: Nedisertib; T0070907; Samotolisib; Torin 2; PP121

MAPK

Ras: Zoledronic acid; AMG 510; Lonafarnib; ARS-1620; Zoledronic acid monohydrate

ERK: Bortezomib; SCH772984; SKI-606; BIX 02189; Resveratrol

Raf: PLX4032; Sorafenib; Sorafenib tosylate; Dabrafenib; Regorafenib

MEK: Trametinib; PD0325901; U0126-EtOH; AZD6244; PD 98059

JNK: SP600125; Doramapimod; JNK-IN-8; Metformin Hydrochloride; Anisomycin

Cell Cycle

Rho: Rhosin hydrochloride; Zoledronic acid; Fasudil (HA-1077) Hydrochloride; NSC 23766 Trihydrochloride; ML141

p21: Dacinostat; APTO-253; Ailanthone; GC7 Sulfate; UC2288

CDK: PD-0332991 (Palbociclib) Hydrochloride; Dinaciclib; Ro-3306; Roscovitine; PF-562271

DNA/RNA Synthesis: PF-562271; Cisplatin; Gemcitabine; 5-Fluorouracil; Cycloheximide

Chk: Oxaliplatin; AZD7762; Rabusertib; MK-8776; CHIR-124; Prexasertib (LY2606368) Dihydrochloride

mAb & ADC

EGFR: Cetuximab; Panitumumab; Cetuximab-MMAE; Serclutamab talirine; Laprituximab emtansine; Depatuxizumab mafodotin; Disitamab vedotin

VEGFR: Bevacizumab; Ramucirumab

MUC16: Sofituzumab vedotin; Oregovomab; Abagovomab; Sofituzumab

GPC3: Codrituzumab; Codrituzumab-MMAE

PD-1: Pembrolizumab; Dostarlimab; Cemiplimab; Camrelizumab; Sintilimab; Nivolumab; Serplulimab

PD-L1: Atezolizumab; Durvalumab; Avelumab; Adebrelimab; Sugemalimab

CTLA-4: Nurulimab; Zalifrelimab; Quavonlimab; Ipilimumab; Tremelimumab

Compound Library

FDA-approved Anticancer Drug Library

Anti-cancer Compound Library

Anti-cancer Compound Library-Ⅱ

Anti-cancer Metabolism Compound Library

Cambridge Cancer Compound Library

Small Molecule Immuno-Oncology Compound Library

Tyrosine Kinase Inhibitor Library

Angiogenesis Related compound Library

MAPK Inhibitor Library

PI3K/Akt Inhibitor Library

References

https://pubmed.ncbi.nlm.nih.gov/31682895/
http://individual.utoronto.ca/faisalnaqib/NCCN/NCCN_Hepatobiliary_Cancers_2022.pdf
https://www.cbioportal.org/study/summary?id=hcc_meric_2021
https://www.cbioportal.org/study/summary?id=ihch_mskcc_2020